Spondyloarthritis & psoriatic arthritis
ASAS recommendations on reporting axial spondyloarthritis clinical trials
Methodological detailsconsensus statement
- Consensus statement
Recommendations
As issued by the authors
- 84% of members in favour
42 baseline features relevant for all axial spondyloarthritis (axSpA) clinical trials and 8 additional features for disease-modifying drug trials defined, with descriptions on how to report them
- 85% of members in favour
How to report 20 trial outcomes (core outcome set (COS)) at baseline and follow-up timepoints
- 93% of members in favour
How to report 11 outcomes of instruments additionally endorsed by ASAS but not in the COS
Original publication
ASAS recommendations on reporting axial spondyloarthritis clinical trials. Ann Rheum Dis. Published 6 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →